Back to Search
MEGAN CLEMONS, PHARMD
PHARMD
Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
NPI: 1669003034Individual
Specialties, Licenses & Credentials
Pharmacist Clinician (PhC)/ Clinical Pharmacy SpecialistPrimary
Pharmacist — Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
Code: 1835P0018X
17920(NV)
Research & Publications (20)
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
PMID 19424729·Support Care Cancer·2010
8-other
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
PMID 19398598·J Clin Pathol·2009
3-trial
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.
PMID 19097882·Eur J Cancer·2009
8-other
Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer.
PMID 19596950·Anticancer Res·2009
8-other
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.
PMID 19266291·Clin Exp Metastasis·2009
8-other
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases.
PMID 19635661·Eur J Cancer·2009
4-observational
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
PMID 19672422·Curr Oncol·2009
8-other
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.
PMID 19551499·Breast Cancer Res Treat·2009
8-other
Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer.
PMID 19433392·Clin Breast Cancer·2009
8-other
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
PMID 19299408·Ann Oncol·2009
3-trial
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
PMID 19299237·Clin Breast Cancer·2009
4-observational
Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
PMID 19360288·Oncol Rep·2009
8-other
Prevention and management of bone metastases in lung cancer: a review.
PMID 19179905·J Thorac Oncol·2009
6-review
Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
PMID 19307138·Crit Rev Oncol Hematol·2009
6-review
Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
PMID 19364633·J Pain Symptom Manage·2009
8-other
Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer.
PMID 18941910·Clin Exp Metastasis·2009
8-other
Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
PMID 19443366·Anticancer Res·2009
8-other
Insulin-lowering effects of metformin in women with early breast cancer.
PMID 19073504·Clin Breast Cancer·2008
3-trial
Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
PMID 18824337·Clin Oncol (R Coll Radiol)·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 175 LEMMON DR
RENO, NV 89506 - Phone
- (775) 971-3320
Quick Facts
- NPI
- 1669003034
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile